Zacks Investment Research downgraded shares of X4 Pharmaceuticals (NASDAQ:XFOR) from a buy rating to a hold rating in a research report report published on Saturday morning, Zacks.com reports.

According to Zacks, “X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. “

XFOR has been the topic of a number of other research reports. ValuEngine downgraded shares of X4 Pharmaceuticals from a strong-buy rating to a buy rating in a report on Wednesday, April 1st. Citigroup reduced their target price on shares of X4 Pharmaceuticals from $16.00 to $15.00 and set a buy rating on the stock in a report on Thursday, March 26th. B. Riley reiterated a buy rating and issued a $15.00 target price on shares of X4 Pharmaceuticals in a research note on Friday, June 12th. Oppenheimer restated a buy rating and issued a $20.00 price objective on shares of X4 Pharmaceuticals in a report on Thursday, May 7th. Finally, Canaccord Genuity reissued a buy rating on shares of X4 Pharmaceuticals in a research report on Tuesday, May 26th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. X4 Pharmaceuticals has a consensus rating of Buy and an average price target of $16.83.

NASDAQ:XFOR opened at $8.12 on Friday. X4 Pharmaceuticals has a one year low of $5.84 and a one year high of $15.95. The stock has a market cap of $131.07 million, a PE ratio of -2.35 and a beta of 0.49. The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.34 and a current ratio of 15.34. The stock has a 50 day moving average price of $8.88 and a 200 day moving average price of $9.33.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Thursday, May 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.27. The company had revenue of $3.00 million during the quarter. As a group, analysts predict that X4 Pharmaceuticals will post -2.73 earnings per share for the current fiscal year.

In other news, CEO Paula Ragan sold 9,707 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $8.88, for a total value of $86,198.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 20,507 shares of company stock worth $181,813. Company insiders own 3.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in XFOR. State Street Corp grew its position in shares of X4 Pharmaceuticals by 23.0% during the 4th quarter. State Street Corp now owns 174,664 shares of the company’s stock worth $1,869,000 after buying an additional 32,657 shares during the period. Barclays PLC lifted its holdings in shares of X4 Pharmaceuticals by 200.1% during the 4th quarter. Barclays PLC now owns 17,563 shares of the company’s stock valued at $188,000 after purchasing an additional 11,711 shares in the last quarter. Citigroup Inc. grew its position in shares of X4 Pharmaceuticals by 304.6% in the 4th quarter. Citigroup Inc. now owns 2,379 shares of the company’s stock valued at $25,000 after purchasing an additional 1,791 shares during the period. Renaissance Technologies LLC bought a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $678,000. Finally, Bain Capital Life Sciences Investors LLC acquired a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $17,639,000. Hedge funds and other institutional investors own 69.78% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on X4 Pharmaceuticals (XFOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for X4 Pharmaceuticals (NASDAQ:XFOR)

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.